Skip to main content
SpringerLink
Log in

CD147 Plasma Levels in Hospitalised Patients with Covid-19 Pneumonia Predict Illness Severity and In-Hospital Mortality

  • Published:
Stem Cell Reviews and Reports Aims and scope Submit manuscript

Abstract

COVID-19 and infectious diseases have been included in strategic development goals (SDG) of United Nations (UN). The CD147 receptor is one of several receptors for the SARS-CoV-2 spike protein that could mediate Covid-19 viral infection of host cells. It has been recently proposed to regulate viral invasion and dissemination among lymphocytes and progenitor/stem cells. A soluble by-product of CD147 (sCD147) exists in plasma and has been previously identified as a marker of diabetes and platelet activation. We examined plasma sCD147 levels in 161 Covid-19 patients at hospital admission. We demonstrated significantly higher plasma sCD147 levels in Covid-19 patients, which correlated with plasma multiorgan dysfunction biomarkers interleukin-6, creatinine and Troponin I. Importantly, sCD147 admission levels were associated with Covid-19 severity and survival, carrying potential value as a biomarker in hospitalized patients with Covid-19 infection.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Data Availability

Raw Data are available upon request to corresponding author.

References

  1. Smadja, D. M., Mentzer, S. J., Fontenay, M., Laffan, M. A., Ackermann, M., Helms, J., et al. (2021). COVID-19 is a systemic vascular hemopathy: Insight for mechanistic and clinical aspects. Angiogenesis, 24(4), 755–788.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. RECOVERY Collaborative Group, Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., et al. (2021). Dexamethasone in Hospitalized Patients with Covid-19. The New England Journal of Medicine, 384(8), 693–704.

    Article  Google Scholar 

  3. Ulrich, H., & Pillat, M. M. (2020). CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. Stem Cell Reviews and Reports, 16(3), 434–440.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Geng, J., Chen, L., Yuan, Y., Wang, K., Wang, Y., Qin, C., et al. (2021). CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal Transduction and Targeted Therapy, 6(1), 347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J. Q., Du, P., et al. (2020). CD147-spike protein is a el route for SARS-CoV-2 infection to host cells. Signal Transduction and Targeted Therapy, 5(1), 283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pennings, G. J., & Kritharides, L. (2014). CD147 in cardiovascular disease and thrombosis. Seminars in Thrombosis and Hemostasis, 40(7), 747–755.

    Article  CAS  PubMed  Google Scholar 

  7. Kuang, Y. H., Liu, Y. J., Tang, L. L., Wang, S. M., Yan, G. J., & Liao, L. Q. (2018). Plasma soluble cluster of differentiation 147 levels are increased in breast cancer patients and associated with lymph node metastasis and chemoresistance. Hong Kong Medical Jornal Xianggang Yi Xue Za Zhi, 24(3), 252–260.

    CAS  Google Scholar 

  8. Philippe, A., Chocron, R., Gendron, N., Bory, O., Beauvais, A., Peron, N., et al. (2021). Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis, 24(3), 505–517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Smadja, D., Gaussem, P., Roncal, C., Fischer, A. M., Emmerich, J., & Darnige, L. (2010). Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome. Lupus, 19(7), 837–843.

    Article  CAS  PubMed  Google Scholar 

  10. Wu, J., Chen, L., Qin, C., Huo, F., Liang, X., Yang, X., et al. (2022). CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis. Signal Transduction and Targeted Therapy, 7(1), 382.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work has been funded with grants from French national agency for research ANR SARCODO (Fondation de France) and Crédit Agricole d’Ile-de-France Mécénat.

Author information

Authors and Affiliations

  1. Université Paris-Cité, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France

    David M. Smadja & Aurélien Philippe

  2. Hematology Department, AP-HP, Georges Pompidou European Hospital, 20 Rue Leblanc, 75015, Paris, France

    David M. Smadja & Aurélien Philippe

  3. Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (Unifesp), São Paulo, Brazil

    Eloara V. M. Ferreira & Rudolf K. F. Oliveira

  4. National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK

    Colm McCabe

  5. National Heart and Lung Institute, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 ONN, UK

    Colm McCabe & Lan Zhao

Authors
  1. David M. Smadja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aurélien Philippe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eloara V. M. Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rudolf K. F. Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Colm McCabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All the undersigning authors have substantially contributed to the paper. LZ and CM developed concepts and implemented the experiments in collaboration with SMD. SMD and AP conducted the sample collection, performed assay and analyzed the data. SMD, AP, LZ and CM interpreted data and wrote the report. SMD and AP provided the figures. EVMF and RO reviewed the data and participated in the finalizing of the report. All authors approved the results. All authors declare that the submitted work is original and has not been published before (neither in English nor in any other language) and that the work is not under consideration for publication elsewhere.

Corresponding authors

Correspondence to David M. Smadja or Lan Zhao.

Ethics declarations

Ethical Approval

Authorization number 2020‐04‐048/ 2020‐A01048‐31/ 20.04.21.49318)—NCT: NCT04624997.

Consent to Participate

The study SARCODO was performed in accordance with the Declaration of Helsinki. All patients provided written informed consent before enrollment.

Consent to Publish

All patients provided written informed consent to have their data published.

Competing Interests

All authors declare no conflict.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Smadja, D.M., Philippe, A., Ferreira, E.V.M. et al. CD147 Plasma Levels in Hospitalised Patients with Covid-19 Pneumonia Predict Illness Severity and In-Hospital Mortality. Stem Cell Rev and Rep 20, 568–572 (2024). https://doi.org/10.1007/s12015-023-10660-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12015-023-10660-9

Keywords

Search

Navigation